GlobeNewsWire
17 Jun 2026, 12:45 UTC · 13w ago
Verdict
Headline takes no side. We score OCUL +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Ocular Therapeutix plans to submit the AXPAXLI NDA for wet AMD in the fourth quarter of 2026 based on SOL-1 data and interim SOL-R safety data.
More positive than 99% of claims this week
The SOL-R efficacy data is no longer required for the AXPAXLI NDA submission, with topline results for the trial now pushed to 1Q 2028.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
Ocular is streamlining its diabetic retinopathy program to prioritize HELIOS-3 as a potential single registrational trial evaluating Q12M dosing.
More positive than 77% of claims this week
The AXPAXLI NDA will be submitted under the 505(b)(2) pathway, potentially accelerating the FDA review timeline by up to 60 days.
More positive than 63% of claims this week
SOL-R trial design has been amended to include a new secondary endpoint evaluating superiority against aflibercept (8mg) at Week 96.
So whatWhile not required for initial approval, proving superiority against a high-dose competitor would significantly increase long-term market share and pricing power.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company announced FDA alignment for its NDA submission, strong clinical data for AXPAXLI, and a streamlined development path for its diabetic retinopathy program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+17.4%
Price agrees with the score
$10.50 vs $8.94 close before publication (Jun 16) · not market-adjusted
OCUL chart →